Thompson A, et al. JAMA 2008;299:2777-88

Study Flow Diagram Thompson A, et al. JAMA 2008;299:2777-88

Description of CETP Genotypes Included in the Review Thompson A, et al. JAMA 2008;299:2777-88

Summary of Data Available on CETP Genotypes, CETP Phenotypes, Lipid Levels, and Coronary Outcomesa Thompson A, et al. JAMA 2008;299:2777-88

Associations of CETP Genotypes With CETP Phenotypes and Lipid Levels CETP indicates cholesteryl ester transfer protein; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. To convert apolipoproteins A-I and B to mg/dL, divide by 0.01; to convert HDL-C and LDL-C to mg/dL, divide by 0.0259; and to convert triglyercides to mg/dL, divide by 0.0113. Assessment of heterogeneity: I2 (95% CI) for CETP mass, CETP activity, HDL-C, apolipoprotein A-I, LDL-C, apolipoprotein B, and triglycerides, respectively, were 66% (39%-81%), 71% (44%-86%), 75% (69%-80%), 66% (46%-78%), 51% (32%-65%), 14% (0%-51%), and 49% (30%-62%) for TaqIB; 0% (0%-71%), NA*, 56% (33%-71%), 0% (0%-68%), 24% (0%-58%), 16% (0%-60%), and 0% (0%-49%) for I405V; and 71% (17%-90%), NA*, 37% (0%-61%), 36% (0%-78%), 29% (0%-63%), 0% (0%-90%), and 0% (0%-57%) for -629CA. NA* indicates I2 statistics were not calculated when there were only 2 studies. aPooled estimates calculated by random-effects models. Estimates calculated by fixed-effect models are shown in eTable 3, available at www.jama.com. bStandardized mean differences. cCalculated with reference to the weighted mean level of each marker in common homozygotes. Thompson A, et al. JAMA 2008;299:2777-88

Mean Differences in HDL-C Levels Associated With CETP Genotypes, Grouped by Recorded Study Characteristics CETP indicates cholesteryl ester transfer protein; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol. To convert HDL-C to mg/dL, divide by 0.0259. Sizes of data markers are proportional to the inverse of the variance of the weighted mean difference. For sex and ethnicity, studies may have contributed data to more than 1 category. Overall estimates were calculated using random-effects models (fixed-effect estimates are provided in eTable 3, available at www.jama.com). Several recorded characteristics explained part of the heterogeneity observed, including ethnicity (P=.008), population source (P=.04), and data source (P<.001) for TaqIB; study size (P=.02) for I405V; and ethnicity (P<.001) and population source (P=.007) for −629C>A. CETP indicates cholesteryl ester transfer protein; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol. To convert HDL-C to mg/dL, divide by 0.0259. Sizes of data markers are proportional to the inverse of the variance of the weighted mean difference. For sex and ethnicity, studies may have contributed data to more than 1 category. Overall estimates were calculated using random-effects models (fixed-effect estimates are provided in eTable 3, available at www.jama.com). Several recorded characteristics explained part of the heterogeneity observed, including ethnicity (P=.008), population source (P=.04), and data source (P.001) for TaqIB; study size (P=.02) for I405V; and ethnicity (P.001) and population source (P=.007) for -629C>A. Thompson A, et al. JAMA 2008;299:2777-88

CETP Genotypes and Coronary Risk, Grouped by Recorded Study Characteristics CETP indicates cholesteryl ester transfer protein; CI, confidence interval. Sizes of data markers are proportional to the inverse of the variance of the loge odds ratio. For ethnicity, source of controls, and outcome assessed, studies may have contributed data to more than 1 category. For ethnicity, results are not presented for 4 studies of TaqIB and 2 studies of I405V and −629C>A that were predominantly based in nonwhite, non−East Asian individuals. For outcome assessed in TaqIB, results are not presented for 1 study that did not provide genotype frequencies separately for cases of myocardial infarction and coronary stenosis. Assessment of heterogeneity: TaqIB (I2=18%; 95% CI, 0%-45%), I405V (I2=39%; 95% CI, 0%-66%), or −629C>A (I2=32%; 95% CI, 0%-62%). Observed heterogeneity could be partially explained by study size (P=.01) and data source (P=.003) for TaqIB and by source of controls (P<.001) for I405V (other comparisons P
.05 for each). Overall estimates were calculated using random-effects models; those calculated using fixed-effect models were 0.96 (95% CI, 0.93-0.99) for TaqIB, 0.95 (95% CI, 0.92-0.99) for I405V, and 0.95 (95% CI, 0.91-0.99) for −629C>A. CETP indicates cholesteryl ester transfer protein; CI, confidence interval. Sizes of data markers are proportional to the inverse of the variance of the loge odds ratio. For ethnicity, source of controls, and outcome assessed, studies may have contributed data to more than 1 category. For ethnicity, results are not presented for 4 studies of TaqIB and 2 studies of I405V and -629CA that were predominantly based in nonwhite, non-East Asian individuals. For outcome assessed in TaqIB, results are not presented for 1 study that did not provide genotype frequencies separately for cases of myocardial infarction and coronary stenosis. Assessment of heterogeneity: TaqIB (I2=18%; 95% CI, 0%-45%), I405V (I2=39%; 95% CI, 0%-66%), or -629C>A (I2=32%; 95% CI, 0%-62%). Observed heterogeneity could be partially explained by study size (P=.01) and data source (P=.003) for TaqIB and by source of controls (P.001) for I405V (other comparisons P.05 for each). Overall estimates were calculated using random-effects models; those calculated using fixed-effect models were 0.96 (95% CI, 0.93-0.99) for TaqIB, 0.95 (95% CI, 0.92-0.99) for I405V, and 0.95 (95% CI, 0.91-0.99) for -629C>A. Thompson A, et al. JAMA 2008;299:2777-88

Observed Per-Allele Odds Ratios for Coronary Disease With CETP Variants vs Odds Ratios Derived From Available Prospective Studies of HDL-C Levels Thompson A, et al. JAMA 2008;299:2777-88